Aktienanalyse zu Altimmune, Inc. (ALT)ALTAltimmune, Inc.

Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed Phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Altimmune Inc is not a good buy right now due to significant recent declines and negative financial indicators. The current price is $2.20, which is down 45% over the past year. The RSI is at a very low 11.51, indicating oversold conditions, but this may not be enough to justify a purchase given the company's ongoing losses, such as a net income loss of $22,825,000 in Q2 2026. The main risk is the company's high debt-to-equity ratio of 7.33% in Q2 2026, which could impact its financial stability moving forward.

1 analysts cover ALT: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 16.00.